Evidence map›Paper›PMID 18845925›Full record

ReviewAIDS (London, England)2008

HIV epidemiology and the effects of antiviral therapy on long-term consequences.

Thomas C Quinn

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in AIDS (London, England), 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
69citing papers in PubMed, 8 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

69 citing papers in PubMed, 8 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Atherosclerosis in HIV Patients: What Do We Know so Far?International journal of molecular sciences · 2022
    Review
  18. Article
  19. Article
  20. Article

9 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Thomas C QuinnJohns Hopkins Center for Global Health, Johns Hopkins University, Baltimore, Maryland, USA. tquinn@jhmi.edu

Funding

International Studies of the Acquired Immune Deficiency Syndrome (AIDS)ZIAAI000361 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI REDD, ANDREW · 2009 to 2025
$15.8M
INTERNATIONAL STUDIES ON THE ACQUIRED IMMUNODEFICIENCY SYNDROMEZ01AI000361 · NIAID · NIAID EXTRAMURAL ACTIVITIES · PI QUINN, THOMAS · 1985 to 2008
$3.1M
Intramural NIH HHS Z01 AI000361
6 · The paper itself

Abstract

Twenty-seven years have now elapsed since the first description of AIDS in homosexual men in San Francisco, USA. Since those early reports in 1981, millions of people have died from this disease and millions are living with HIV infection worldwide. The rate of new cases of HIV infection has stabilized in some parts of the developed world, but in other areas of the world, especially in Africa, south-east Asia and eastern Europe, the number of newly infected individuals continues to rise alarmingly. Despite international commitment, there is still much to be done to improve access to antiretroviral drugs in areas of greatest need, especially sub-Saharan Africa. The availability of antiretroviral drugs is a key factor in limiting the pandemic and prolonging the lives of those infected, but a more universal, targeted approach, incorporating prevention, early diagnosis, counselling and treatment, will only succeed in stemming the spread of the virus. In the face of the apparent inability to control the increasing rate of new infections there are some positive signs in the battle against HIV/AIDS. In developed countries, the introduction of antiretroviral drugs has resulted in a significant reduction in AIDS-related mortality and improved survival. As access to antiretroviral drugs in the developing world improves, it is hoped that these trends will begin to be reflected worldwide. As HIV/AIDS shifts from a fatal to a chronic disease, however, a new range of health complications and threats to mortality are beginning to arise.

Indexed as

Antiretroviral Therapy, Highly ActiveAntiviral AgentsDisease OutbreaksFemaleGlobal HealthHealth EducationHealth Services AccessibilityHIV-1HIV InfectionsHomosexualityHumansMalePrognosisRisk FactorsAntiviral Agents

Identifiers

PMID18845925
PMCPMC2753265

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.